MONTREAL, QUEBEC--(Marketwire - October 26, 2007) - Theratechnologies (TSX: TH) today presented its first scientific symposium in HIV-associated lipodystrophy to increase the awareness of this disease at the 11th European AIDS Conference (EACS) in Madrid, Spain. Theratechnologies also presented additional positive 52-week safety data from its tesamorelin (TH9507) Phase 3 clinical trial at EACS. The new data, presented in a late-breaker session, are in line with the safety profile of tesamorelin observed during the initial 26 weeks of treatment. Overall, tesamorelin was well tolerated by patients and signals no concerns with respect to glucose intolerance after one year of treatment.
